Hartaj Singh
Stock Analyst at Oppenheimer
(1.53)
# 3,063
Out of 4,670 analysts
106
Total ratings
42.31%
Success rate
-10.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Hartaj Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATXS Astria Therapeutics | Maintains: Outperform | $26 → $28 | $9.65 | +190.16% | 6 | Nov 14, 2024 | |
| GILD Gilead Sciences | Maintains: Outperform | $95 → $105 | $90.19 | +16.42% | 13 | Nov 7, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,150 → $1,000 | $738.00 | +35.50% | 12 | Nov 6, 2024 | |
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $372.89 | +60.91% | 7 | Oct 31, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $550 → $540 | $450.97 | +19.74% | 16 | Oct 30, 2024 | |
| MRNA Moderna | Downgrades: Perform | n/a | $41.11 | - | 8 | Sep 13, 2024 | |
| SPRB Spruce Biosciences | Maintains: Outperform | $4 → $3 | $0.48 | +520.73% | 5 | Jun 13, 2024 | |
| CLLS Cellectis | Maintains: Outperform | $11 → $10 | $1.87 | +434.76% | 5 | Jun 12, 2024 | |
| BMEA Biomea Fusion | Maintains: Outperform | $70 → $60 | $6.44 | +831.68% | 5 | May 30, 2024 | |
| VIRX Viracta Therapeutics | Maintains: Outperform | $13 → $11 | $0.16 | +6,745.05% | 3 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $180 | $114.23 | +57.58% | 9 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $1.72 | +423.26% | 4 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $4.07 | +882.80% | 4 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $18.80 | +17.02% | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $16 | $3.16 | +406.35% | 3 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.14 | - | 3 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $650 | $1.17 | +55,455.56% | 1 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $19.00 | +57.89% | 1 | Jan 26, 2018 |
Astria Therapeutics
Nov 14, 2024
Maintains: Outperform
Price Target: $26 → $28
Current: $9.65
Upside: +190.16%
Gilead Sciences
Nov 7, 2024
Maintains: Outperform
Price Target: $95 → $105
Current: $90.19
Upside: +16.42%
Regeneron Pharmaceuticals
Nov 6, 2024
Maintains: Outperform
Price Target: $1,150 → $1,000
Current: $738.00
Upside: +35.50%
United Therapeutics
Oct 31, 2024
Maintains: Outperform
Price Target: $575 → $600
Current: $372.89
Upside: +60.91%
Vertex Pharmaceuticals
Oct 30, 2024
Maintains: Outperform
Price Target: $550 → $540
Current: $450.97
Upside: +19.74%
Moderna
Sep 13, 2024
Downgrades: Perform
Price Target: n/a
Current: $41.11
Upside: -
Spruce Biosciences
Jun 13, 2024
Maintains: Outperform
Price Target: $4 → $3
Current: $0.48
Upside: +520.73%
Cellectis
Jun 12, 2024
Maintains: Outperform
Price Target: $11 → $10
Current: $1.87
Upside: +434.76%
Biomea Fusion
May 30, 2024
Maintains: Outperform
Price Target: $70 → $60
Current: $6.44
Upside: +831.68%
Viracta Therapeutics
May 23, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $0.16
Upside: +6,745.05%
May 14, 2024
Upgrades: Outperform
Price Target: $180
Current: $114.23
Upside: +57.58%
Apr 23, 2024
Maintains: Outperform
Price Target: $9
Current: $1.72
Upside: +423.26%
Mar 8, 2024
Maintains: Outperform
Price Target: $40
Current: $4.07
Upside: +882.80%
Jan 5, 2024
Initiates: Outperform
Price Target: $22
Current: $18.80
Upside: +17.02%
Sep 13, 2023
Maintains: Outperform
Price Target: $31 → $16
Current: $3.16
Upside: +406.35%
Apr 4, 2023
Downgrades: Perform
Price Target: n/a
Current: $1.14
Upside: -
Nov 1, 2018
Initiates: Outperform
Price Target: $650
Current: $1.17
Upside: +55,455.56%
Jan 26, 2018
Maintains: Outperform
Price Target: $24 → $30
Current: $19.00
Upside: +57.89%